Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.2K
Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

3.1K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
3.1K
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

1.7K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.7K
Inhaled Medications01:23

Inhaled Medications

1.0K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.0K
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

1.0K
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
1.0K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in the treatment of anaphylaxis: intranasal and sublingual versus intramuscular epinephrine.

Current opinion in allergy and clinical immunology·2025
Same author

Getting in Shape: Updates in Exercise Anaphylaxis.

Current allergy and asthma reports·2024
Same author

Identifying thresholds of reaction for different foods.

Journal of food allergy·2024
Same author

Evidence-based use of epinephrine in anaphylaxis.

Current opinion in allergy and clinical immunology·2024
Same author

Yardstick for managing cough, part 2: In children.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2023
Same author

Update in primary immune deficiencies for the practicing allergist/clinical immunologist.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2022
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Venom Anaphylaxis.

Immunology and allergy clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Apr 5, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

31.6K

Novel Epinephrine Delivery Devices.

Nicole O' Malley1, Jay Adam Lieberman1

  • 1Division of Pulmonology, Allergy & Immunology, Department of Pediatrics, University of Tennessee Health Science Center, LeBonheur Children's Hospital, Memphis, TN, USA.

Immunology and Allergy Clinics of North America
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Novel, needle-free epinephrine delivery via intranasal or sublingual routes shows promise for anaphylaxis treatment. These methods offer similar pharmacokinetics to autoinjectors, with intranasal devices now available for prescription.

Keywords:
AnaphylaxisBarriersEpinephrineInjectableIntranasalSublingual

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K

Related Experiment Videos

Last Updated: Apr 5, 2026

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

31.6K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
04:22

Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals

Published on: March 30, 2017

8.1K

Area of Science:

  • Allergy and Immunology
  • Pharmacology
  • Emergency Medicine

Background:

  • Research is exploring novel, non-injectable epinephrine delivery methods.
  • Intranasal and sublingual routes aim for needle-free epinephrine administration.
  • These routes seek to achieve pharmacokinetics comparable to traditional autoinjectors.

Purpose of the Study:

  • To review recent research on non-injectable epinephrine delivery routes.
  • To inform clinicians about needle-free epinephrine options for anaphylaxis.
  • To support shared decision-making regarding epinephrine use.

Main Methods:

  • Literature review of studies on intranasal and sublingual epinephrine.
  • Analysis of pharmacokinetic data comparing non-injectable routes to autoinjectors.
  • Inclusion of information on currently available intranasal epinephrine devices.

Main Results:

  • Non-injectable routes, including intranasal, can achieve pharmacokinetics similar to autoinjectors.
  • An intranasal epinephrine device is now available for prescription for at-risk patients.
  • These findings support the viability of needle-free epinephrine options.

Conclusions:

  • Clinicians need to be aware of emerging non-injectable epinephrine delivery systems.
  • Shared decision-making is crucial for determining the appropriateness of non-injectable epinephrine for patients.
  • Non-injectable epinephrine represents a significant advancement in anaphylaxis management.